nach oben

Current Oncology Reports

Erschienen in:

01.11.2010 | Clinical Trial Report

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

verfasst von: Amit Mahipal, Mark Weiss

Erschienen in: Current Oncology Reports | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Excerpt

Robak T, Dmoszynska A, Solal-Celigny P, et al.: Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010, 28:1756–1765. …

Dighiero G, Hamblin TJ: Chronic lymphocytic leukaemia. Lancet 2008, 371:1017–1029.CrossRefPubMed

Weiss MA, Maslak PG, Jurcic JG, et al.: Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol 2003, 21:1278–1284.CrossRefPubMed

Eichhorst BF, Busch R, Hopfinger G, et al.: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006, 107:885–891.CrossRefPubMed

Tam CS, O’Brien S, Wierda W, et al.: Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008, 112:975–980.CrossRefPubMed

Wierda W, O’Brien S, Wen S, et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005, 23:4070–4078.CrossRefPubMed

Lamanna N, Kalaycio M, Maslak P, et al.: Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol 2006, 24:1575–1581.CrossRefPubMed

Lamanna N, Jurcic JG, Noy A, et al.: Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses. J Clin Oncol 2009, 27:491–497.CrossRefPubMed

Foon KA, Boyiadzis M, Land SR, et al.: Chemoimmunotherapy with low-dose fludarabine and cyclophosphamide and high dose rituximab in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:498–503.CrossRefPubMed

10.

Eichhorst BF, Busch R, Stilgenbauer S, et al.: First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia. Blood 2009, 114:3382–3391.CrossRefPubMed

11.

Hallek M, Fingerle-Rowson G, Fink AM, et al.: First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL study group [abstract 535]. Blood (ASH Annual Meeting Abstracts) 2009, 114:Abstract 535.

Titel: The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia
verfasst von: Amit Mahipal
Mark Weiss
Publikationsdatum: 01.11.2010
Verlag: Current Science Inc.
Erschienen in: Current Oncology Reports / Ausgabe 6/2010
Print ISSN: 1523-3790
Elektronische ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-010-0122-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

The Addition of Rituximab to Fludarabine and Cyclophosphamide Improves Progression-free Survival in Patients with Previously Treated Chronic Lymphocytic Leukemia

Excerpt

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2010

Childhood Rhabdomyosarcoma: New Insight on Biology and Treatment

Is Maintenance Rituximab Now Ready for PRIMA-Time?

Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

State-of-the-art Issues in Hodgkin’s Lymphoma Survivorship

Can Anthracycline Therapy for Pediatric Malignancies Be Less Cardiotoxic?

Targeted Signal Transduction Therapies in Myeloid Malignancies

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie